| Aug 12 |
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia, the Prototypic Nociplastic Pain Syndrome, at the IASP 2024 World Congress on Pain
|
| Aug 7 |
CDC says clinicians should remain alert for potential monkeypox cases
|
| Aug 6 |
Tonix Pharmaceuticals Announces Publication in Microorganisms of Technology that Expands Company’s Capabilities in Generating Potential Therapeutic Fully Human Antibodies Against SARS-CoV-2 and Other Pathogens
|
| Aug 1 |
FDA Recognizes Fibromyalgia as a 'Serious Condition' And Fast-Tracks New Drug Candidate
|
| Jul 31 |
Tonix Pharmaceuticals Announces Potential Positive Impact of the U.S. National Academies (NASEM) New Definition of Long COVID on the Size of the Fibromyalgia Market for Tonmya™
|
| Jul 30 |
Tonix Pharmaceuticals Announces Poster Presentation at the IASP 2024 World Congress on Pain
|
| Jul 25 |
Tonix Pharma gains on FDA fast track tag for pain therapy
|
| Jul 25 |
Tonix Pharmaceuticals Granted Fast Track Designation by FDA for Tonmya™ for Fibromyalgia
|
| Jul 24 |
Beyond "One Bug, One Drug" - Tonix Pharmaceuticals Secures Up To $34 Million In Funding From The U.S. Department Of Defense To Develop a Broad-Spectrum Antiviral
|
| Jul 18 |
TNXP: High Interest in Tonmya Seen in Initial Findings from Market Opportunity Analysis…
|
